

# Swiss Inflammatory Bowel Diseases Cohort Study (SIBDCS)

## COMPLETE LIST OF SCIENTIFIC PUBLICATIONS

Updated on **December 15, 2023**

1. Martinho-Gruerber M, Kapoglou I, Bravo F, Sarraj R, Benz E, Restellini S, Biedermann L, Rogler G, Vavricka SR, Schoepfer A, Maillard MH, Michetti P, Brunner F, Clair C, Barry MP, Pittet V, von Känel R, Juillerat P. Alcohol and cannabis consumption in patients with inflammatory bowel disease: prevalence, pattern of consumption and impact on the disease. *Eur J Gastroenterol Hepatol*. 2023 Jan 1;35(1):21-30.
2. Salzmann M, von Graffenried T, Righini-Grunder F, Braegger C, Spalinger J, Schibli S, Schoepfer A, Nydegger A, Pittet V\*, Sokollik C\*; Swiss IBD Cohort Study Group. Drug-Related Adverse Events Necessitating Treatment Discontinuation in Pediatric Inflammatory Bowel Disease Patients. *J Pediatr Gastroenterol Nutr*. 2022 Dec 1;75(6):731-736.
3. Santi G, Michetti P, Froehlich F, Rossel JB, Pittet V, Maillard MH. Adherence to Recommendations and Quality of Endoscopic Colorectal Cancer Surveillance in Long-Standing Ulcerative Colitis. *Inflamm Intest Dis*. 2021 Feb;6(1):25-31.
4. Lautenschlager SA, Fournier N, Biedermann L, Pittet V, Schreiner P, Misselwitz B, Scharl M, Rogler G, Siebenhüner AR. The Influence of Breastfeeding, Cesarean Section, Pet Animals, and Urbanization on the Development of Inflammatory Bowel Disease: Data from the Swiss IBD Cohort Study. *Inflamm Intest Dis*. 2020 Nov;5(4):170-179.
5. Schreiner P, Rossel JB, Biedermann L, Valko PO, Baumann CR, Greuter T, Scharl M, Vavricka SR, Pittet V, Juillerat P, Rogler G, von Känel R, Misselwitz B; Swiss IBD Cohort Study Group. Fatigue in inflammatory bowel disease and its impact on daily activities. *Aliment Pharmacol Ther*. 2021 Jan;53(1):138-149
6. Greuter T, Manser C, Pittet V, Vavricka SR, Biedermann L; on behalf of Swiss IBDnet. Gender Differences in Inflammatory Bowel Disease. *Digestion*. 2020;101 Suppl 1:98-104. doi: 10.1159/000504701. Epub 2020 Jan 29.
7. Pillai N, Lupatsch JE, Dusheiko M, Schwenkglenks M, Maillard M, Sutherland CS, Pittet VEH; Swiss IBD Cohort study group. Evaluating the cost-effectiveness of early compared to late or no biologic treatment to manage Crohn's disease using real world data. 2020 May 21;14(4):490-500. doi: 10.1093/ecco-jcc/jjz169.
8. Schreiner P, Yilmaz B, Rossel JB, Franc Y, Misselwitz B, Scharl M, Zeitz J, Frei P, Greuter T, Vavricka SR, Pittet V, Siebenhüner A, Juillerat P, von Känel R, Macpherson AJ, Rogler G, Biedermann L; Swiss IBD Cohort Study Group. Vegetarian or gluten-free diets in patients with inflammatory bowel disease are associated with lower psychological well-being and a different gut microbiota, but no beneficial effects on the course of the disease. *United European Gastroenterol J*. 2019 Jul;7(6):767-781
9. Pittet V, Maillard MH, Simonson T, Fournier N, Rogler G, Michetti P. Differences in Outcomes Reported by Patients With Inflammatory Bowel Diseases vs Their Health Care Professionals. *Clin Gastroenterol Hepatol*. 2019 Sep;17(10):2050-2059.
10. Bon L, Scharl S, Vavricka S, Rogler G, Fournier N, Pittet V, Scharl M, Greuter T, Schreiner P, Frei P, Misselwitz B, Biedermann L, Zeitz J; Swiss IBD Cohort Study Group. Association of IBD specific treatment and prevalence of pain in the Swiss IBD cohort study. *PLoS One*. 2019 Apr 25;14(4):e0215738.
11. Pillai N, Dusheiko M, Maillard MH, Rogler G, Brüngger B, Bähler C, Pittet VEH on behalf of the Swiss IBD cohort study group. The evolution of healthcare utilisation and costs for inflammatory bowel disease over ten years. *J Crohn Colitis*. 2019 May 27;13(6):744-754.
12. Pittet V, Michetti P, Mueller C, Braegger CP, von Känel R, Schoepfer A, Macpherson AJ, Rogler G. Cohort Profile Update: The Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS). *Int J Epidemiol*. 2019 Apr 1;48(2):385-386f.
13. Yilmaz B, Juillerat P, Øyås O, Ramon C, Bravo FD, Franc Y, Fournier N, Michetti P, Mueller C, Geuking M, Pittet VEH, Maillard MH, Rogler G; Swiss IBD Cohort Investigators, Wiest R, Stelling J, Macpherson AJ. Microbial network disturbances in relapsing refractory Crohn's disease. *Nat Med*. 2019 Apr;25(4):701.

14. Pittet V, Vaucher C, Froehlich F, Maillard MH, Michetti P; Swiss IBD Cohort Study Group. Patient-reported healthcare expectations in inflammatory bowel diseases. *PLoS One*. 2018 May 17;13(5):e0197351
15. Rouiller-Braunschweig C, Fournier N, Pittet V, Dudler J, Michetti P. Efficacy, Safety and Mucosal Healing of Methotrexate in a Large Longitudinal Cohort of Inflammatory Bowel Disease Patients. *Digestion*. 2017 Oct 24;96(4):220-227.
16. Pillai N, Dusheiko M, Burnand B, Pittet V. A systematic review of cost-effectiveness studies comparing conventional, biological and surgical interventions for inflammatory bowel disease. *PLoS One*. 2017 Oct 3;12(10):e0185500. Review.
17. Pittet V, Vaucher C, Froehlich F, Burnand B, Michetti P, Maillard MH; Swiss IBD Cohort Study Group. Patient self-reported concerns in inflammatory bowel diseases: A gender-specific subjective quality-of-life indicator. *PLoS One*. 2017 Feb 10;12(2):e0171864
18. Schreiner P, Biedermann L, Rossel JB, Rogler G, Pittet V, von Känel R; Swiss IBD Cohort Study Group. Prevalence and Determinants of Job Stress in Patients with Inflammatory Bowel Disease. *Inflamm Bowel Dis*. 2017 Feb;23(2):310-317
19. Schüle S, Rossel JB, Frey D, Biedermann L, Scharl M, Zeitz J, Freitas-Queiroz N, Pittet V, Vavricka SR, Rogler G, Misselwitz B; Swiss IBD cohort study. Prediction of low bone mineral density in patients with inflammatory bowel diseases. *United European Gastroenterol J*. 2016 Oct;4(5):669-676.
20. Fraga M, Fournier N, Safroneeva E, Pittet V, Godat S, Straumann A, Nydegger A, Vavricka SR, Moradpour D, Schoepfer AM; Swiss IBD Cohort Study Group. Primary sclerosing cholangitis in the Swiss Inflammatory Bowel Disease Cohort Study: prevalence, risk factors, and long-term follow-up. *Eur J Gastroenterol Hepatol*. 2017 Jan;29(1):91-97.
21. Vaucher C, Maillard MH, Froehlich F, Burnand B, Michetti P, Pittet V. Patients and gastroenterologists' perceptions of treatments for inflammatory bowel diseases: do their perspectives match? *Scand J Gastroenterol*. 2016 Sep;51(9):1056-61.
22. Mikocka-Walus A, Pittet V, Rossel JB, von Känel R; Swiss IBD Cohort Study Group. Symptoms of Depression and Anxiety Are Independently Associated With Clinical Recurrence of Inflammatory Bowel Disease. *Clin Gastroenterol Hepatol*. 2016 Jun;14(6):829-835.e1.
23. Mueller R, Ziade F, Pittet V, Fournier N, Ezri J, Schoepfer A, Schibli S, Spalinger J, Braegger C, Nydegger A; Swiss IBD Cohort Study. Quality of Life in Swiss Paediatric Inflammatory Bowel Disease Patients: Do Patients and Their Parents Experience Disease in the Same Way? *J Crohns Colitis*. 2016 Mar;10(3):269-76. doi: 10.1093/ecco-jcc/jjv199. Epub 2015 Oct 29.
24. Zeitz J, Ak M, Müller-Mottet S, Scharl S, Biedermann L, Fournier N, Frei P, Pittet V, Scharl M, Fried M, Rogler G, Vavricka S; Swiss IBD Cohort Study Group. Pain in IBD Patients: Very Frequent and Frequently Insufficiently Taken into Account. *PLoS One*. 2016 Jun 22;11(6):e0156666.
25. Pittet V, Vaucher C, Maillard MH, Girardin M, de Saussure P, Burnand B, Rogler G, Michetti P. Information Needs and Concerns of Patients with Inflammatory Bowel Disease: What Can We Learn from Participants in a Bilingual Clinical Cohort? *PLoS One*. 2016 Mar 3;11(3):e0150620. doi: 10.1371/journal.pone.0150620. eCollection 2016.
26. Ditisheim S, Fournier N, Juillerat P, Pittet V, Michetti P, Gabay C, Finckh A; Swiss IBD Cohort Study Group. Inflammatory Articular Disease in Patients with Inflammatory Bowel Disease: Result of the Swiss IBD Cohort Study. *Inflamm Bowel Dis*. 2015 Nov;21(11):2598-604.
27. Safroneeva E, Vavricka SR, Fournier N, Pittet V, Peyrin-Biroulet L, Straumann A, Rogler G, Schoepfer AM; Swiss IBD Cohort Study Group. Impact of the early use of immunomodulators or TNF antagonists on bowel damage and surgery in Crohn's disease. *Aliment Pharmacol Ther*. 2015 Oct;42(8):977-89
28. Biedermann L, Fournier N, Misselwitz B, Frei P, Zeitz J, Manser CN, Pittet V, Juillerat P, von Känel R, Fried M, Vavricka S, Rogler G. High rates of smoking especially in female Crohn's disease patients and low use of supportive measures to achieve smoking cessation - Data from the SwissIBD cohort study. *J Crohns Colitis*. 2015 Oct;9(10):819-29.
29. Multone E, Vader JP, Mottet C, Schoepfer A, Fournier N, Burnand B, Michetti P, Pittet V. Characteristics of non-responders to self-reported questionnaires in a large inflammatory bowel disease cohort study. *Scand J Gastroenterol*. 2015;50(11):1348-56.
30. Burkhalter H, Stucki-Thür P, David B, Lorenz S, Biotti B, Rogler G, Pittet V. Assessment of inflammatory bowel disease patient's needs and problems from a nursing perspective. *Digestion*. 2015;91(2):128-41

31. Pittet V, Maillard MH, Lauvergeon S, Timmer M, Michetti P, Froehlich F, Burnand B, Vader JP, Mottet C. Acceptance of Inflammatory Bowel Disease Treatment Recommendations Based on Appropriateness Ratings: do Practicing Gastroenterologists Agree with Experts? *J Crohns Colitis* (2015) 9 (2): 132-139
32. Schoepfer AM, Bortolotti M, Pittet V, Mottet C, Gonvers JJ, Reich O, Fournier N, Vader JP, Burnand B, Michetti P, Froehlich F. The gap between scientific evidence and clinical practice: 5-aminosalicylates are frequently used for the treatment of Crohn's disease. *Aliment Pharmacol Ther.* 2014 Oct;40(8):930-7
33. Hiroz P, Vavricka SR, Fournier N, Safroneeva E, Pittet V, Rogler G, Schoepfer AM; Swiss IBD Cohort Study Group. Analysis of TNF-antagonist switch over time and associated risk factors in the Swiss Inflammatory Bowel Disease Cohort. *Scand J Gastroenterol.* 2014 Oct;49(10):1207-18.
34. Maillard MH, Bortolotti M, Vader JP, Mottet C, Schoepfer A, Gonvers JJ, Burnand B, Froehlich F, Michetti P, Pittet V; The Swiss IBD Cohort Study Group. Appropriateness and long-term discontinuation rate of biological therapies in ulcerative colitis. *J Crohns Colitis.* 2014 Aug 1;8(8):825-34.
35. Pittet V, Rogler G, Mottet C, Froehlich F, Michetti P, de Saussure P, Burnand B, Vader JP; the Swiss IBD Cohort Study Group. Patients' information-seeking activity is associated with treatment compliance in inflammatory bowel disease patients. *Scand J Gastroenterol.* 2014 Jun;49(6):662-73.
36. Rogler D, Fournier N, Pittet V, Bühr P, Heyland K, Friedt M, Koller R, Rueger V, Herzog D, Nydegger A, Schäppi M, Schibli S, Spalinger J, Rogler G, Braegger CP; the Swiss IBD Cohort Study Group. Coping is excellent in Swiss Children with inflammatory bowel disease: Results from the Swiss IBD cohort study. *J Crohns Colitis.* 2014 May 1;8(5):409-20.
37. Seibold F, Fournier N, Beglinger C, Mottet C, Pittet V, Rogler G, and the Swiss IBD cohort study group. Topical therapy is underused in patients with ulcerative colitis. *J Crohns Colitis* 2014 Jan;8(1):56-63.
38. Pittet V, Froehlich F, Maillard MH, Mottet C, Gonvers JJ, Felley C, Vader JP, Burnand B, Michetti P, Schoepfer A, and the EPACK-II Update Panellists. When do we dare to stop biological or immunomodulatory therapy for Crohn's disease? Results of a multidisciplinary European expert panel. *J Crohns Colitis* 2013;7:820-6.
39. Pittet V, Rogler G, Michetti P, Fournier N, Vader JP, Schoepfer A, Mottet C, Burnand B, Froehlich F, Swiss Inflammatory Bowel Disease Cohort Study G. Penetrating or stricturing diseases are the major determinants of time to first and repeat resection surgery in Crohn's disease. *Digestion* 2013;87:212-21.
40. Rogler D, Fournier N, Pittet V, Bühr P, Heyland K, Friedt M, Koller R, Rueger V, Herzog D, Nydegger A, Schäppi M, Schibli S, Spalinger J, Rogler G, Braegger CP; the Swiss IBD Cohort Study Group. Coping is excellent in Swiss Children with inflammatory bowel disease: Results from the Swiss IBD cohort study. *J Crohns Colitis.* 2013 Nov 11.
41. Seibold F, Fournier N, Beglinger C, Mottet C, Pittet V, Rogler G, and the Swiss IBD cohort study group. Topical therapy is underused in patients with ulcerative colitis. *J Crohns Colitis* 2013.
42. Schoepfer AM, Dehlavi MA, Fournier N, Safroneeva E, Straumann A, Pittet V, Peyrin-Biroulet L, Michetti P, Rogler G, Vavricka SR. Diagnostic Delay in Crohn's Disease Is Associated With a Complicated Disease Course and Increased Operation Rate. *Am J Gastroenterol* 2013.
43. Schoepfer AM, Beglinger C, Straumann A, Safroneeva E, Romero Y, Armstrong D, Schmidt C, Trummel M, Pittet V, Vavricka SR. Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger Index, C-reactive protein, platelets, hemoglobin, and blood leukocytes. *Inflamm Bowel Dis* 2013;19:332-41.
44. Herzog D, Landolt MA, Buehr P, Heyland K, Rogler D, Koller R, Rueger V, Pittet V, Nydegger A, Spalinger J, Schappi M, Schibli S, Braegger CP, and the Swiss IBD cohort study group. Low prevalence of behavioural and emotional problems among Swiss paediatric patients with inflammatory bowel disease. *Arch Dis Child* 2013;98:16-9.
45. Vavricka SR, Spigaglia SM, Rogler G, Pittet V, Michetti P, Felley C, Mottet C, Braegger CP, Rogler D, Straumann A, Bauerfeind P, Fried M, Schoepfer AM, and the Swiss IBD cohort study group. Systematic evaluation of risk factors for diagnostic delay in inflammatory bowel disease. *Inflamm Bowel Dis* 2012;18:496-505.
46. Scharl M, Mwinyi J, Fischbeck A, Leucht K, Eloranta JJ, Arikkat J, Pesch T, Kellermeier S, Mair A, Kullak-Ublick GA, Truninger K, Noreen F, Regula J, Gaj P, Pittet V, Mueller C, Hofmann C, Fried M, McCole DF,

- Rogler G. Crohn's disease-associated polymorphism within the PTPN2 gene affects muramyl-dipeptide-induced cytokine secretion and autophagy. *Inflamm Bowel Dis* 2012;18:900-12.
47. Camara RJ, Juillerat P, Pittet V, Schoepfer AM, Begre S, von Kanel R, and the Swiss IBD cohort study group. Quality of life: a potentially useful measure to indicate subclinical flares in Crohn disease. *Intern Med J* 2012;42:e145-51.
  48. Vavricka SR, Brun L, Ballabeni P, Pittet V, Prinz Vavricka BM, Zeitz J, Rogler G, Schoepfer AM. Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. *Am J Gastroenterol* 2011;106:110-9.
  49. Camara RJ, Schoepfer AM, Pittet V, Begre S, von Kanel R, and the Swiss IBD cohort study group. Mood and nonmood components of perceived stress and exacerbation of Crohn's disease. *Inflamm Bowel Dis* 2011;17:2358-65.
  50. Camara RJ, Lukas PS, Begre S, Pittet V, von Kanel R, and the Swiss IBD cohort study group. Effects of social support on the clinical course of Crohn's disease. *Inflamm Bowel Dis* 2011;17:1277-86.
  51. Braegger CP, Ballabeni P, Rogler D, Vavricka SR, Friedt M, Pittet V, and the Swiss IBD cohort study group. Epidemiology of inflammatory bowel disease: Is there a shift towards onset at a younger age? *J Pediatr Gastroenterol Nutr* 2011;53:141-4.
  52. Voegtlin M, Vavricka SR, Schoepfer AM, Straumann A, Voegtlin J, Rogler G, Ballabeni P, Pittet V, Buser A, Fried M, Beglinger C, and the Swiss IBD cohort study group. Prevalence of anaemia in inflammatory bowel disease in Switzerland: a cross-sectional study in patients from private practices and university hospitals. *J Crohns Colitis* 2010;4:642-8.
  53. Pittet V, Juillerat P, Michetti P, Vader JP, Burnand B, Rogler G, Beglinger C, Seibold F, Mottet C, Felley C, Gonvers JJ, Froehlich F, and the Swiss IBD cohort study group. Appropriateness of therapy for fistulizing Crohn's disease: findings from a national inflammatory bowel disease cohort. *Aliment Pharmacol Ther* 2010;32:1007-16.
  54. Juillerat P, Pittet V, Vader JP, Burnand B, Gonvers JJ, de Saussure P, Mottet C, Seibold F, Rogler G, Sagmeister M, Felley C, Michetti P, Froehlich F, and the Swiss IBD cohort study group. Infliximab for Crohn's disease in the Swiss IBD Cohort Study: clinical management and appropriateness. *Eur J Gastroenterol Hepatol* 2010;22:1352-7.
  55. Pittet V, Juillerat P, Mottet C, Felley C, Ballabeni P, Burnand B, Michetti P, Vader JP, and the Swiss IBD cohort study group. Cohort profile: the Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS). *Int J Epidemiol* 2009;38:922-31.